Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of INDV-6200 in Healthy Volunteers
NCT03715634Phase 1Completed
- Sponsor
- Indivior
- Start
- Sep 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in opioid use disorder (OUD) comparing Depot buprenorphine (INDV-6200) with Placebo (2 arms). Primary endpoint: Assessment of PK of INDV-6200 (buprenorphine) at 84 days. Started Sep 2017; status: completed.
02
Drugs
INDV-6200
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03715634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03715634.